Literature for inhibitor I51.002: phosphatidylethanolamine-binding protein

(Topics flags: S Structure. To select only the references relevant to a single topic, click the link above. See explanation.)

2020
1. [YEAR:26-6-2020]
   Expression of Concern: Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src
   J Biol Chem295, 8883-8883. PubMed  Europe PubMed DOI
2004
2. [YEAR:15-9-2004]Keller,E.T., Fu,Z. and Brennan,M.
   The role of Raf kinase inhibitor protein (RKIP) in health and disease
   Biochem Pharmacol68, 1049-1053. PubMed  Europe PubMed DOI
2001
3. [YEAR:5-1-2001]Hengst,U., Albrecht,H., Hess,D. and Monard,D.
   The phosphatidylethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors
   J Biol Chem276, 535-540. PubMed  Europe PubMed DOI
4. [YEAR:13-7-2001]Serre,L., Pereira de Jesus,K., Zelwer,C., Bureaud,N., Schoentgen,F. and Benedetti,H.
   Crystal structures of YBHB and YBCL from Escherichia coli, two bacterial homologues to a Raf kinase inhibitor protein
   J Mol Biol310, 617-634. PubMed  Europe PubMed DOI  S